Categories AlphaGraphs, Earnings

Alexion beats earnings and sales estimates; raises guidance

Shares of biopharma company Alexion (ALXN) opened up 7% when market started today after it reported a rise in Q1 2018 earnings and revenue, and lifted the guidance for the year. Along with this, the company also reported a positive top line results for its Phase 3 study.

The company that specializes in manufacturing drugs for rare disorder reported a 7% increase in its revenue to $930.9 million. Earnings per share rose 48% to $1.11 and excluding items, the company’s earnings per share rose 22% during the quarter.

Net product sales of the key drug Soliris, which accounts for a bulk of the company’s revenue and is used to treat serious genetic-based blood condition, grew 2% during the quarter to $800.1 million.

Alexion has been working aggressively on rebuilding its pipeline. This is one of the reasons why it recently acquired Wilson Therapeutics based in Sweden. This deal, valued at $855 million, gives Alexion a greater control over the Wilson’s rare disease drug WTX101. Also, this new drug will reduce the company’s complete dependence on Soliris for generating revenue. The transaction is expected to close during the second quarter of this year.

The drugmaker also reported positive topline results for its Phase 3 study that is again used to treat a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH).

The company also raised its guidance for revenue and adjusted EPS for the full year. Alexion now expects its revenue to be in the range of about $3.93 to 3.99 billion, up from the previous estimate of $3.85 to $3.95 billion and adjusted EPS to be about $6.75 to $6.90, up from the prior estimate of $6.60 to $6.80.

Today, apart from Alexion, two other drugmakers reported their results before the market opened. While AbbVie (ABBV) reported strong results and trades in the positive territory, Bristol-Myers Squibb (BMY) shares were down 1% in the morning session. Vertex Pharmaceuticals (VRTX) will announce its quarterly results after the market closes today.

Alexion earnings infographic
Alexion Pharmaceuticals Q1 2018 Earnings Infographic

Most Popular

Infographic: Nvidia (NVDA) Q4 revenue up 61%; earnings beat

Nvidia Corporation (NASDAQ: NVDA) Wednesday said its fourth-quarter revenues and profit increased in double-digits amid elevated demand. The results also topped the Street view, driving the stock higher during the

Nutanix (NTNX) Earnings: 2Q21 Key Numbers

Nutanix (NASDAQ: NTNX) reported second quarter 2021 earnings results today. Total revenue remained flat at $346.4 million compared to the same period a year ago. GAAP net loss was $287.3

Macy’s (M) expects digital channels to generate approx. $10 billion in sales by 2023

Shares of Macy’s Inc. (NYSE: M) were down 2.7% in morning trade on Wednesday. The stock has gained 37% since the beginning of the year. A day ago, the retailer

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top